Back to News
Market Impact: 0.5

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

INTUBMOMSRBLXCAZNSMMTMRKNEENOW
Company FundamentalsCorporate EarningsAnalyst InsightsTechnology & InnovationHealthcare & BiotechEnergy Markets & PricesM&A & RestructuringRegulation & Legislation
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Benzinga's latest Stock Whisper Index highlights five stocks garnering significant investor attention, each driven by distinct catalysts. Intuit (INTU) and Roblox (RBLX) are experiencing strong analyst upgrades and operational momentum, with INTU potentially benefiting from new tax legislation. AstraZeneca (AZN) interest is fueled by reported talks for a substantial $15 billion drug partnership, while NextEra Energy (NEE) navigates legislative impacts on clean energy while also benefiting from a renewed nuclear energy push. ServiceNow (NOW) is gaining traction due to its AI advancements and consistent financial performance, with all five companies facing upcoming Q2 earnings reports that could further define their near-term trajectories.

Analysis

Benzinga's Stock Whisper Index has identified five companies with significant near-term catalysts, creating distinct profiles for investor consideration ahead of their Q2 earnings. Intuit (INTU) and Roblox (RBLX) exhibit strong momentum, with both trading near all-time highs and benefiting from bullish analyst sentiment. Intuit's outlook is bolstered by price target increases from BMO (to $870) and Morgan Stanley (to $900) and a potential legislative tailwind from the "One Big Beautiful Bill," which could drive user growth for TurboTax. Roblox is seeing aggressive price target hikes from BTIG (to $124) and Citigroup (to $123), fueled by strong user monetization and a seven-quarter streak of beating EPS estimates. AstraZeneca's (AZN) investor interest is primarily driven by M&A speculation, specifically reported talks for a potential $15 billion partnership with Summit Therapeutics for a lung cancer drug that has shown superior data to Merck's Keytruda. This focus on strategic growth appears to overshadow the company's mixed recent earnings history, which includes missing EPS estimates in five of the last six quarters. In contrast, NextEra Energy (NEE) faces a more complex outlook, with potential pressure from the rollback of clean energy incentives under the new bill, partially offset by its leverage to a renewed push in nuclear energy. The company's five consecutive revenue misses make its upcoming earnings a critical event for clarity. Lastly, ServiceNow (NOW) presents a disconnect between strong fundamentals—including beating EPS estimates in nine of the last ten quarters and making progress in AI—and its 11% year-to-date stock decline, setting a high bar for its Q2 report to potentially realign its valuation with its performance.